Sposito C, Di Sandro S, Brunero F, Buscemi V, Battiston C, Lauterio A, Bongini M, De Carlis L, Mazzaferro V. Development of a prognostic scoring system for resectable hepatocellular carcinoma. World J Gastroenterol 2016; 22(36): 8194-8202 [PMID: 27688661 DOI: 10.3748/wjg.v22.i36.8194]
Corresponding Author of This Article
Vincenzo Mazzaferro, MD, PhD, Gastrointestinal Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, University of Milan, Via Venezian 1, 20133 Milan, Italy. vincenzo.mazzaferro@istitutotumori.mi.it
Research Domain of This Article
Surgery
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Sposito C, Di Sandro S, Brunero F, Buscemi V, Battiston C, Lauterio A, Bongini M, De Carlis L, Mazzaferro V. Development of a prognostic scoring system for resectable hepatocellular carcinoma. World J Gastroenterol 2016; 22(36): 8194-8202 [PMID: 27688661 DOI: 10.3748/wjg.v22.i36.8194]
World J Gastroenterol. Sep 28, 2016; 22(36): 8194-8202 Published online Sep 28, 2016. doi: 10.3748/wjg.v22.i36.8194
Development of a prognostic scoring system for resectable hepatocellular carcinoma
Carlo Sposito, Stefano Di Sandro, Federica Brunero, Vincenzo Buscemi, Carlo Battiston, Andrea Lauterio, Marco Bongini, Luciano De Carlis, Vincenzo Mazzaferro
Carlo Sposito, Carlo Battiston, Marco Bongini, Vincenzo Mazzaferro, Gastrointestinal Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, University of Milan, 20133 Milan, Italy
Stefano Di Sandro, Vincenzo Buscemi, Andrea Lauterio, Luciano De Carlis, General Surgery and Organ Transplants, Ospedale Niguarda Ca’Granda, 20133 Milan, Italy
Federica Brunero, Clinical Trial Office and Biomedical Statistic, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy
Author contributions: Sposito C drafted the manuscript and supervised the study; Di Sandro S and Brunero F analyzed the data; Buscemi V, Lauterio A and Bongini M collected the data; Battiston C, De Carlis L and Mazzaferro V revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the Fondazione IRCCS Istituto Nazionale Tumori of Milan.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: No conflicts of interest are declared by the authors with respect to the material and methodology presented in the manuscript.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at vincenzo.mazzaferro@istitutotumori.mi.it. Consent for data sharing was not obtained from participants, but the presented data are anonymised, and risk of identification is absent.
Correspondence to: Vincenzo Mazzaferro, MD, PhD, Gastrointestinal Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, University of Milan, Via Venezian 1, 20133 Milan, Italy. vincenzo.mazzaferro@istitutotumori.mi.it
Telephone: +39-2-23902760 Fax: +39-2-23903259
Received: May 27, 2016 Peer-review started: May 30, 2016 First decision: July 13, 2016 Revised: August 16, 2016 Accepted: August 30, 2016 Article in press: August 30, 2016 Published online: September 28, 2016 Processing time: 121 Days and 9.6 Hours
Core Tip
Core tip: European Association for the Study of the Liver (EASL)/American Association for the Study of Liver Diseases (AASLD) guidelines recommend liver resection (LR) for hepatocellular carcinoma (HCC) only for single nodules of any size in patients without tumor related symptoms, no clinically significant portal hypertension and normal bilirubin. In this study we investigated the prognostic factors for survival of patients who underwent LR for HCC. We built a prognostic scoring system to stratify post-resection prognosis, and we identified a larger subset of patients with an expected survival that equates that of patients undergoing LR according to guidelines. Thus, the current EASL/AASLD indications for LR can be safely expanded, with no detrimental effect on patients’ prognosis.
